Novel proteins and nucleic acids encoding same
First Claim
Patent Images
1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
- (a) a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS;
2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25;
(b) a variant of a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS;
2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;
(c) an amino acid sequence selected from the group consisting of SEQ ID NOS;
2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25; and
(d) a variant of an amino acid sequence selected from the group consisting of SEQ ID NOS;
2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence.
1 Assignment
0 Petitions
Accused Products
Abstract
Disclosed herein are novel human nucleic acid sequences which encode polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.
16 Citations
49 Claims
-
1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
-
(a) a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS;
2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25;(b) a variant of a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS;
2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form;(c) an amino acid sequence selected from the group consisting of SEQ ID NOS;
2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25; and(d) a variant of an amino acid sequence selected from the group consisting of SEQ ID NOS;
2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence. - View Dependent Claims (2, 3, 4, 15, 16, 17, 18, 22, 23, 24, 25, 26, 27, 28, 29, 34, 35, 36, 37, 38, 40, 41, 43, 44, 45, 49)
-
-
5. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of:
-
(a) a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS;
2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25;(b) a variant of a mature form of an amino acid sequence selected from the group consisting of SEQ ID NOS;
2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form,provided that said variant differs in no more than 15% of the amino acid residues from the amino acid sequence of said mature form; (c) an amino acid sequence selected from the group consisting of SEQ ID NOS;
2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25;(d) a variant of an amino acid sequence selected from the group consisting of SEQ ID NOS;
2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence;(e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising an amino acid sequence chosen from the group consisting of SEQ ID NOS;
2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25, or a variant of said polypeptide, wherein one or more amino acid residues in said variant differs from the amino acid sequence of said mature form, provided that said variant differs in no more than 15% of amino acid residues from said amino acid sequence; and(f) a nucleic acid molecule comprising the complement of (a), (b), (c), (d) or (e). - View Dependent Claims (6, 7, 8, 9, 10, 11, 12, 13, 14, 19, 20, 21, 30, 31, 32, 33, 39, 42, 46, 47)
-
-
48. A method of treating a pathological state in a mammal, the method comprising administering to the mammal a polypeptide in an amount that is sufficient to alleviate the pathological state, wherein the polypeptide is a polypeptide having an amino acid sequence at least 95% identical to a polypeptide comprising an amino acid sequence of at least one of SEQ ID NOS:
- 2, 4, 6, 8, 13, 15, 17, 19, 21, 23, and 25, or a biologically active fragment thereof.
Specification